Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial

• Recce Pharmaceuticals (ASX:RCE) completes dosing of the first male and female subjects in its UTI/urosepsis clinical trial at the highest concentration of R327
• The dosing lasts 15 minutes at 3000mg and was approved by an independent safety committee unanimously to run faster
• The company recruited a full cohort and is dosing the last remaining patients in the coming days
• RCE shares are up 2.33 per cent, trading at 44 cents at 12:37 pm AEDT

Recce Pharmaceuticals (ASX:RCE) has completed dosing the first male and female subjects in its UTI clinical trial at the highest concentration of Recce 327 (R327).

The dosing was completed in 15-minute intervals at 3000 milligrams within Recce’s phase I/II UTI/urosepsis clinical trial, and it has been approved by an independent safety committee unanimously to be administered at a faster interval.

“To be dosing at twice the speed of the last cohort to 3000mg over 15 minutes via intravenous administration is a testament to the safety and tolerability profile of R327, another important clinical milestone for the company,” RCE CEO James Graham said.

The company recruited a full cohort and is dosing the last remaining patients in the coming days.

RCE shares were up 2.33 per cent, trading at 44 cents at 12:37 pm AEDT.